Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

210.61 +1.74 (+0.83%)
Streaming Delayed Price Updated: 12:26 PM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive... 
Via MarketMinute
News headline image
Why Biogen Stock Sank While the Market Soared on Thursday ↗
It's reaching into its coffers for a $5.6 billion acquisition. 
Via The Motley Fool
News headline image
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to... 
Via MarketMinute
Gapping S&P500 stocks in Tuesday's session ↗
Via Chartmill
Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi ↗
Via Stocktwits
Top S&P500 movers in Tuesday's session ↗
Via Chartmill
News headline image
Spotlight Movers: APLS, VTIX, ELAB, ARTL Fuel Multi-Sector Momentum
Via AB Newswire
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY).... 
Via Finterra
Topics Economy Intellectual Property
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
From Biogen Inc.
Via GlobeNewswire
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
From Biogen Inc.
Via GlobeNewswire
News headline image
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
From Biogen Inc.
Via GlobeNewswire
News headline image
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
From Biogen Inc.
Via GlobeNewswire
News headline image
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Value Stocks Walking a Fine Line
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call
Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales.... 
Via StockStory
Topics Earnings
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
Biogen Announces Board Chair Transition
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair 
From Biogen Inc.
Via GlobeNewswire
News headline image
BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds
Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share... 
Via StockStory
News headline image
Why Biogen Stock Surged Almost 9% Higher on Friday ↗
It's obvious that the company has a good shot at returning to growth. 
Via The Motley Fool
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,... 
Via MarketMinute
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.